NASDAQ:ARAV Aravive (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 09/16/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Aravive Stock (NASDAQ:ARAV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aravive alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aravive, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies that address mechanisms of tumor progression and treatment resistance. The company’s lead product candidate, AVB-500, is a high-affinity soluble receptor decoy designed to neutralize growth arrest-specific 6 (Gas6) and inhibit signaling through the Axl receptor tyrosine kinase. By targeting the Gas6/Axl pathway, Aravive aims to enhance the effectiveness of existing therapies and overcome resistance in oncology indications. AVB-500 is currently being evaluated in multiple Phase 2 clinical studies, including trials in platinum-resistant ovarian cancer and metastatic renal cell carcinoma, where it is administered in combination with standard-of-care treatments. In addition to its oncology programs, Aravive is exploring the role of Gas6/Axl signaling in fibrotic diseases, leveraging translational biomarkers and strategic collaborations to advance its preclinical candidates. The company’s development strategy emphasizes rigorous clinical design and partnerships to expedite the path to potential regulatory approval. Founded in 2015 and headquartered in Houston, Texas, Aravive operates clinical trial sites across North America and Europe. The company is led by Chief Executive Officer R. Joseph Eustace, whose experience in oncology drug development is complemented by a leadership team with deep expertise in translational science, clinical operations and regulatory affairs. Together, Aravive’s management is dedicated to translating novel scientific insights into therapeutic solutions for patients with high unmet needs.AI Generated. May Contain Errors. Read More Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARAV Stock News HeadlinesOut-of-state companies win grants for trials at Houston's MD Anderson Cancer CenterNovember 27, 2024 | bizjournals.comAdial Pharmaceuticals Appoints Vinay Shah To Succeed Joseph Truluck As CFONovember 5, 2024 | markets.businessinsider.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved. | Banyan Hill Publishing (Ad)Global Automated Cell Culture Market to Exhibit Significant Growth at a CAGR of ~7% by 2030 | DelveInsightOctober 17, 2024 | finance.yahoo.comHouston-based health supplements co. to delist from Nasdaq, dissolveOctober 3, 2024 | bizjournals.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightApril 2, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comSee More Headlines ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? Aravive's stock was trading at $0.0401 at the beginning of the year. Since then, ARAV shares have increased by 0.0% and is now trading at $0.0401. How were Aravive's earnings last quarter? Aravive, Inc (NASDAQ:ARAV) announced its earnings results on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.46) by $0.07. The company had revenue of $2.41 million for the quarter, compared to analysts' expectations of $2.36 million. When did Aravive IPO? Aravive (ARAV) raised $120 million in an initial public offering (IPO) on Thursday, March 20th 2014. The company issued 6,000,000 shares at a price of $19.00-$21.00 per share. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aravive investors own include NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Meta Platforms (META). Company Calendar Last Earnings10/27/2021Today9/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARAV CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees20Year Founded2008Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data BetaN/A Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ARAV) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredGold Miners Post Record Cash Flow Even as Prices Pull BackThe four largest gold miners are generating record free cash flow, even with gold pulling back from recent hig...Golden Portfolio | Sponsored$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash ...Monument Traders Alliance | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
